Search Results
May 11, 2026, 11:40 ET LabGenomics Unifies QDx and IMD Under One Brand
pathology supported by subspecialty expertise, including, gastroenterology, urology, dermatopathology, cytology, women's health, immunohistochemistry (IHC) and biomarker testing, flow cytometry, cytogenetics and chromosomal analysis, Fluorescence In Situ Hybridization (FISH), PCR and RT-PCR assays, next-generation
More news about: LabGenomics
May 08, 2026, 06:47 ET 蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療PD-L1陽性NSCLC的sNDA獲NMPA受理
；2)經EGFR-TKI和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的HR+/HER2- (IHC 0、IHC 1+或IHC 2+/ISH-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲國家藥品監督管理局(NMPA)授予6項突破性療法認定(BTD)。蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2
More news about: 科倫博泰
May 08, 2026, 06:40 ET The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been
More news about: Kelun-Biotech
Apr 27, 2026, 07:45 ET Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
metastatic HER2+ GEA (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Patients were randomized to the three trial arms: zanidatamab in combination with chemotherapy
More news about: Jazz Pharmaceuticals plc
Apr 22, 2026, 07:00 ET Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant
More news about: Labcorp
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been
More news about: Kelun-Biotech
Apr 21, 2026, 20:28 ET 2026 ASCO | 科倫博泰3項研究成果入選2026美國臨床腫瘤學會年會口頭彙報
；2)經EGFR-TKI和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的HR+/HER2- (IHC 0、IHC 1+或IHC 2+/ISH-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床意義上的獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲國家藥品監督管理局(NMPA)授予6項突破性療法認定(BTD)。蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2
More news about: 科倫博泰
Apr 21, 2026, 16:05 ET Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
vivo.[1] In the United States, Ziihera is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 The FDA granted accelerated approval for this indication based on overall
More news about: Jazz Pharmaceuticals plc
Apr 21, 2026, 10:01 ET Paradigm Health Launches SPIRE to Accelerate Late-Phase Clinical Evidence Generation
evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors: DESTINY-PanTumor04."SPIRE builds on Paradigm Health's category-leading technology platform, including its
More news about: Paradigm Health, Inc.
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
a sterically masked CD3 binding arm designed to restrict T-cell activation to the tumor microenvironment.Results: Tissue microarray IHC analysis showed that ALPP/G expression was restricted to placental tissue among normal organs and was not detected in other normal tissues, while frequent
More news about: Antengene Corporation Limited
Apr 17, 2026, 15:00 ET Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
#4415/23] AI-powered analysis of millions of IHC images identifies 19 spatially highly co-expressed protein pairs to enable bispecific antibody developmentApril 21, 9:00 AM - 12:00 PM,
More news about: Lunit
Apr 16, 2026, 08:00 ET Revolune and MindPeak to Showcase Integrated Multiplex Immunofluorescence Workflow at AACR 2026
analysis. About Revolune Revolune is a life science company dedicated to advancing spatial biology through streamlined multiplex immunofluorescence solutions at the ease of IHC. By developing reagent technologies designed for clarity, speed, and confidence, Revolune enables researchers to reveal critical biological insights
More news about: Revolune
Apr 16, 2026, 08:00 ET Revolune and MindPeak to Showcase Integrated Multiplex Immunofluorescence Workflow at AACR 2026
analysis. About Revolune Revolune is a life science company dedicated to advancing spatial biology through streamlined multiplex immunofluorescence solutions at the ease of IHC. By developing reagent technologies designed for clarity, speed, and confidence, Revolune enables researchers to reveal critical biological insights
More news about: Revolune
Apr 16, 2026, 08:00 ET Revolune und MindPeak präsentieren auf der AACR 2026 einen integrierten Workflow für die Multiplex-Immunfluoreszenz
Weiterentwicklung der räumlichen Biologie durch optimierte Lösungen für die Multiplex-Immunfluoreszenz widmet, die so einfach anzuwenden sind wie die IHC. Durch die Entwicklung von Reagenzien, die auf Klarheit, Schnelligkeit und Zuverlässigkeit ausgelegt sind, ermöglicht Revolune Forschern, wichtige biologische
More news about: Revolune
Apr 16, 2026, 08:00 ET Revolune y MindPeak presentarán su flujo de trabajo integrado de inmunofluorescencia multiplex en la AACR 2026
ciencias biológicas dedicada al avance de la biología espacial mediante soluciones de inmunofluorescencia multiplex optimizadas, con la facilidad de la IHC. Al desarrollar tecnologías de reactivos diseñadas para ofrecer claridad, rapidez y fiabilidad, Revolune permite a los investigadores descubrir información
More news about: Revolune
Apr 16, 2026, 08:00 ET À l'occasion d'AACR 2026, Revolune et MindPeak présentent un flux de travail intégré d'immunofluorescence multiplexe
cliniques. Fondée en 2018, la technologie d'IA de Mindpeak permet aux laboratoires d'extraire des informations exploitables des images de tissus H&E, IHC et mIF, allant de la quantification des biomarqueurs subcellulaires à la stratification prédictive des patients. Les solutions soutiennent à la fois
More news about: Revolune
Apr 15, 2026, 08:30 ET Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
sent to Caris receives profiling through Whole Exome Sequencing (WES) of DNA, Whole Transcriptome Sequencing (WTS) of RNA and immunohistochemistry (IHC) analysis of proteins, covering more than 23,000 genes.A proprietary trial-matching platform then cross-references each patient's molecular results
More news about: Caris Life Sciences
Apr 15, 2026, 08:00 ET Revolune GmbH Launches to Simplify Spatial Biology with Streamlined Multiplex Immunofluorescence Solutions
emphasizes workflow reliability, ease of adoption, and experimental confidence, supporting scientists in generating reproducible multiplexing at the ease of IHC workflows.Florian Leiss brings deep expertise in spatial biology and life science technology development. Prior to founding Revolune, he led strategic
More news about: Revolune
Apr 15, 2026, 08:00 ET Revolune GmbH Launches to Simplify Spatial Biology with Streamlined Multiplex Immunofluorescence Solutions
emphasizes workflow reliability, ease of adoption, and experimental confidence, supporting scientists in generating reproducible multiplexing at the ease of IHC workflows.Florian Leiss brings deep expertise in spatial biology and life science technology development. Prior to founding Revolune, he led strategic
More news about: Revolune
Apr 15, 2026, 08:00 ET Die Revolune GmbH geht an den Start, um die räumliche Biologie durch optimierte Lösungen für die Multiplex-Immunfluoreszenz zu vereinfachen
Einführung und experimentelle Zuverlässigkeit und unterstützt Wissenschaftler dabei, reproduzierbare Multiplex-Analysen mit der Einfachheit von IHC-Arbeitsabläufen zu generieren.Florian Leiss bringt fundiertes Fachwissen in den Bereichen räumliche Biologie und Technologieentwicklung in den
More news about: Revolune
Apr 15, 2026, 08:00 ET Revolune GmbH se lanza para simplificar la biología espacial
experimental, lo que ayuda a los científicos a generar multiplexación reproducible con la facilidad de los flujos de trabajo de inmunohistoquímica (IHC).Florian Leiss aporta una amplia experiencia en biología espacial y desarrollo de tecnologías para las ciencias de la vida. Antes de fundar Revolune,
More news about: Revolune
Apr 13, 2026, 20:00 ET 双双入選2026 SGO口頭報告：蘆康沙妥珠單抗(sac-TMT)兩項婦科腫瘤研究成果發佈
LC；既往至少接受過2種系統治療(其中至少1種治療針對晚期或轉移性階段)的不可切除的局部晚期或轉移性TNBC；經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的HR+/HER2- (IHC 0、IHC 1+或IHC 2+/ISH-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲NMPA授予6項突破性療法認定(BTD)。蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲准上市的TROP2
More news about: 科倫博泰
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications listed above have
More news about: Kelun-Biotech
Apr 10, 2026, 07:00 ET Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
CancerMUC16 has high, tumor‑selective expression, with concordance between MUC16 mRNA expression and MUC16 protein abundance by IHC.MUC16 is highly expressed across most histologic subtypes, including the most common subtype, high-grade serous ovarian carcinoma (HGSOC), which
More news about: Whitehawk Therapeutics, Inc.
Mar 30, 2026, 03:15 ET Lunit, CellCarta Announce Strategic Collaboration to Accelerate AI-Enabled Digital Pathology for Companion Diagnostic Programs
pathology products within CellCarta workflows to support biomarker strategy, quantitative image analysis, including quantitative immunohistochemistry (IHC) and immune phenotyping, clinical trial testing, and CDx readiness—especially in high-complexity or structurally constrained scenarios where platform
More news about: Lunit